Viewing data from:

ERYTHROCIN STEARATE

ANDA

ERYTHROMYCIN STEARATE | A060359 | AZURITY PHARMACEUTICALS INC

3 strengths0 unique patents0 unique exclusivities

Medicare Part D Spending

CMS annual spending data for Erythrocin Stearate (2023)

Total Spending

$9K

Total Claims

Beneficiaries

—

Avg Cost/Unit

$10.52

Spending Trend

$521K(2020)→$156K(2021)→$5K(2022)→$9K(2023)

YoY Change:+18.3%

5yr CAGR:+2.3%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain5 active DMFs14 inactive

5 active API suppliers hold Drug Master Files for this ingredient.

ABBVIE INCERYTHROMYCIN STEARATE

DMF 133721998

CALYX CHEMICALS AND PHARMACEUTICALS LTDERYTHROMYCIN STEARATE

DMF 220612008

MAHIMA LIFE SCIENCES PRIVATE LTDERYTHROMYCIN STEARATE USP

DMF 278912013

SM BIOMED SDN BHDERYTHROMYCIN STEARATE USP

DMF 321202017

CENTURY PHARMACEUTICALS LTDERYTHROMYCIN STEARATE USP

DMF 345822020

DIASPA TRADE MARK STRIDES ITALIA SRLInactiveERYTHROMYCIN STEARATE

DMF 133151998

ABBOTT FERMENTATION PRODUCTS DE PUERTO RICO INCInactiveERYTHROMYCIN STEARATE

DMF 133241998

PHARMACIA AND UPJOHNInactiveERYTHROMYCIN STEARATE

DMF 133611998

POLFAInactiveERYTHROMYCIN STEARATE

DMF 133931998

IBIInactiveERYTHROMYCIN STEARATE

DMF 133811998

FERMIC SA DE CVInactiveERYTHROMYCIN STEARATE

DMF 134591998

DSM CAPUA SPAInactiveERYTHROMYCIN STEARATE

DMF 134451998

ARCHIFAR LABInactiveERYTHROMYCIN STEARATE

DMF 134781998

ERCROS INDUSTRIAL SA FYSEInactiveERYTHROMYCIN STEARATE

DMF 134671998

ABBOTT LABORATORIES CHEMICAL AND AGRICULTURAL PRODUCTS DIVInactiveERYTHROMYCIN STEARATE

DMF 135101998

PFIZER INCInactiveERYTHROMYCIN STEARATE

DMF 135301998

CIBRANInactiveERYTHROMYCIN STEARATE

DMF 136921998

ANGUS BIOTECH INCInactiveERYTHROMYCIN STEARATE

DMF 137341998

COMPANHIA INDUSTRIAL PRODUTORA DE ANTIBIOTICOS SARLInactiveERYTHROMYCIN STEARATE

DMF 142451999

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (3)

Sort:

#001 — EQ 250MG BASE

0 patents0 exclusivities▴

TABLET;ORAL | Approved: Approved Prior to Jan 1, 1982

No patent or exclusivity listings for this strength.

#002 — EQ 125MG BASE

0 patents0 exclusivities▾

TABLET;ORAL | Approved: Approved Prior to Jan 1, 1982

#003 — EQ 500MG BASE

0 patents0 exclusivities▾

TABLET;ORAL | Approved: Approved Prior to Jan 1, 1982